Victory Capital Management Inc. Purchases 6,467 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Victory Capital Management Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 24.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,679 shares of the biopharmaceutical company’s stock after buying an additional 6,467 shares during the quarter. Victory Capital Management Inc.’s holdings in TG Therapeutics were worth $764,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in TGTX. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the period. Quarry LP raised its holdings in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 503 shares during the period. Private Advisor Group LLC raised its holdings in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after purchasing an additional 542 shares during the period. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares in the last quarter. Finally, nVerses Capital LLC grew its holdings in shares of TG Therapeutics by 34.9% in the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,500 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TGTX shares. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright lifted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. increased their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday. B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Up 2.2 %

Shares of TGTX stock opened at $35.00 on Friday. The firm’s fifty day moving average price is $26.19 and its two-hundred day moving average price is $22.04. TG Therapeutics, Inc. has a 1 year low of $12.32 and a 1 year high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $5.45 billion, a P/E ratio of -349.97 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 EPS. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.